Molecular Partners is a biotechnology business based in the US. Molecular Partners shares (MOLN) are listed on the NASDAQ and all prices are listed in US Dollars. Molecular Partners employs 167 staff and has a trailing 12-month revenue of around $6.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.90 |
|---|---|
| 52-week range | $3.32 - $12.70 |
| 50-day moving average | $5.53 |
| 200-day moving average | $4.55 |
| Wall St. target price | $9.13 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.9 from 2024-07-25
| 1 week (2024-07-19) | -10.35% |
|---|---|
| 1 month (2024-06-27) | -16.33% |
| 3 months (2024-04-26) | 52.06% |
| 6 months (2024-01-26) | 26.61% |
| 1 year (2023-07-27) | -5.60% |
|---|---|
| 2 years (2022-07-27) | -6.79% |
| 3 years (2021-07-27) | 19.94 |
| 5 years (2019-07-26) | 13.1 |
| Revenue TTM | $6.7 million |
|---|---|
| Gross profit TTM | $138.9 million |
| Return on assets TTM | -17.98% |
| Return on equity TTM | -29.96% |
| Profit margin | 0% |
| Book value | $5.13 |
| Market Capitalization | $223 million |
TTM: trailing 12 months
We're not expecting Molecular Partners to pay a dividend over the next 12 months.
Over the last 12 months, Molecular Partners's shares have ranged in value from as little as $3.32 up to $12.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Partners's is 0.67. This would suggest that Molecular Partners's shares are less volatile than average (for this exchange).
To put Molecular Partners's beta into context you can compare it against those of similar companies.
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. .
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.